Classifying fatty liver disease using liver biopsy
Part of Digestive system, Hormones & metabolism clinical trials.
This study aims to better classify a common type of fatty liver disease (called MAFLD) using liver biopsy samples. It may help researchers understand different subtypes of the disease and could lead to more personalized care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a fatty liver confirmed by ultrasound, plus at least one metabolic risk factor such as being overweight, high blood sugar, high triglycerides, low HDL cholesterol, or high blood pressure.
- You must have already had a liver biopsy done (or be able to have one).
- You must not drink a lot of alcohol (more than about 2 drinks a day for men or 1 drink a day for women).
- You must not have hepatitis B or C.
- You must not have a history of cancer, heart disease, chronic kidney disease, severe liver cirrhosis, or a liver transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study aims to build a tool to predict how MASLD-related cirrhosis (fatty liver disease leading to liver scarring) will progress. It may help doctors and patients better understand the outlook and plan care.
This study asks people with metabolic fatty liver disease and liver scarring about their experiences. It aims to learn what matters to you so doctors can improve care.
This study looks at whether the natural chemicals made by your gut bacteria from the food you eat could affect liver fat and health. If you have MASLD (a fatty liver condition), researchers want to measure these gut-produced substances to better understand the disease.
This study is testing whether advanced imaging and other non-invasive methods can properly identify people with significant liver scarring due to metabolic liver disease or alcohol-related liver disease. It may help find better ways to track liver health without repeated needle biopsies.
This study tests a new drug called ALN-CIDEB for people with fatty liver disease (MASLD or MASH). The goal is to see if it can reduce liver fat and improve liver health. You may qualify if you have a higher BMI and evidence of liver fat on imaging tests.
This study uses routine blood tests to find people with advanced liver scarring caused by a condition called MASLD. If you are between 50 and 75, have certain metabolic risks, and get blood work from your primary care doctor at select centers, you may be eligible.
Hear when a new Metabolic Dysfunction-Associated Steatotic Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.